Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,590 GBX | +0.59% | +5.53% | +18.77% |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- With a 2024 P/E ratio at 22.22 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+18.77% | 248B | B+ | ||
+43.64% | 749B | C+ | ||
+39.42% | 605B | B | ||
-6.58% | 351B | C+ | ||
+19.72% | 328B | B- | ||
+8.78% | 292B | C+ | ||
+11.92% | 216B | B- | ||
-2.62% | 214B | A+ | ||
+0.03% | 167B | C+ | ||
+6.13% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AZN Stock
- Ratings AstraZeneca PLC